Noe Macias-Segura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Noe Macias-Segura has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Julio Enrique Castañeda Delgado
Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico
4 shared publications - Cesar Ramos-Remus
Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud , Sierra Mojada 950, Independencia Oriente, Guadalajara, Jalisco 44340
3 shared publications - José Antonio Enciso-Moreno
Unidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México.
3 shared publications Leonor Enciso-Moreno
Medical research Unit of Zacatecas, Mexican Institute of Social Security, UIMZ-IMSS , Zacatecas , Mexico
3 shared publications- Carmen Judith Serrano
Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Interior de la Alameda # 45, Zacatecas 98000, Mexico
2 shared publications M. Zapata-Zuñiga
Hospital Rural # 51, IMSS, Villanueva, Zacatecas, Mexico; Facultad de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas, Zacatecas, México
2 shared publications
Latest Publications
- Open Access
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 554.4
Gene expression profile and cytokine analysis in experimental autoimmune encephalomyelitis (EAE) in AVP deficient rats
Introduction: Human Multiple Sclerosis (MS) is a medically important disease. MS and its experimental autoimmune encephalomyelitis (EAE) paradigm are central nervous system demyelinizing diseases in which the immune system is directly involved. The pursuit for new treatments for MS still as an important goal for research. The use of the EAE animals to study the immune mechanisms that mediate the disease still being the best strategy to deep into the immune‐neuroendocrine interactions during the pathogenesis. Previously we have demonstrated that neurointermediate pituitary lobectomy (NIL) decreases humoral and cell‐mediated immune responses and that AVP is directly involved. Nevertheless, the role of AVP has not been entirely clarified. Objective: To investigate the mechanism by which AVP deficiency (by NIL) and desmopressin (DP, a synthetic analog of AVP) affects the development of the clinical signs, the immune response and gene expression profile in the EAE. Methods: Female Lewis rats were divided into intact control (IC), EAE immunized, NIL and NIL treated with desmopressin (NIL+DP). Except the IC, the remaining groups were immunized for EAE. The EAE was induced by encephalitogen subcutaneous injection. Animals were sacrificed at the peak of the disease (15 days after immunization). EAE clinical signs, cytokine serum profiles (IL‐17A, IL‐4, IL‐2, IL‐10, IL‐6, TNF‐α and INF‐γ) (flow cytometry) and spleen gene expression profile (microarray) were evaluated. DP treatment started 3 days before immunization. Results: As compared with the EAE group, NIL animals developed just a mild clinical signs of EAE and significant decreased IFN‐γ and IL‐17 levels. NIL+DP treated animals restored its susceptibility to EAE clinical signs, whereas no‐significant differences on cytokine levels occurred. Significant differences in gene expression profile among groups were evident; in the NIL group the expression pattern of the TGF‐β pathway was down‐regulated as compared with the EAE group, whereas in the NIL+DP group the same genes were up‐regulated. Conclusions: Findings add novel data indicating that directly AVP plays a crucial role in regulating the immune responses and suggests that AVP receptor blockers may be used for the MS treatment and possibly autoimmune diseases and other inflammatory processes. Support or Funding Information Supported by UAA‐PIFF14‐1 and CONACYT‐221262 (AQS). México. VVB: CONACT Doctoral scholarship. NMS: CONACYT post doctoral Fellow. México. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , 554.4
Open AccessGene expression profile and cytokine analysis in experimental autoimmune encephalomyelitis (EAE) in AVP deficient rats
Introduction: Human Multiple Sclerosis (MS) is a medically important disease. MS and its experimental autoimmune encephalomyelitis (EAE) paradigm are central nervous system demyelinizing diseases in which the immune system is directly involved. The pursuit for new treatments for MS still as an important goal for research. The use of the EAE animals to study the immune mechanisms that mediate the disease still being the best strategy to deep into the immune‐neuroendocrine interactions during the pathogenesis. Previously we have demonstrated that neurointermediate pituitary lobectomy (NIL) decreases humoral and cell‐mediated immune responses and that AVP is directly involved. Nevertheless, the role of AVP has not been entirely clarified. Objective: To investigate the mechanism by which AVP deficiency (by NIL) and desmopressin (DP, a synthetic analog of AVP) affects the development of the clinical signs, the immune response and gene expression profile in the EAE. Methods: Female Lewis rats were divided into intact control (IC), EAE immunized, NIL and NIL treated with desmopressin (NIL+DP). Except the IC, the remaining groups were immunized for EAE. The EAE was induced by encephalitogen subcutaneous injection. Animals were sacrificed at the peak of the disease (15 days after immunization). EAE clinical signs, cytokine serum profiles (IL‐17A, IL‐4, IL‐2, IL‐10, IL‐6, TNF‐α and INF‐γ) (flow cytometry) and spleen gene expression profile (microarray) were evaluated. DP treatment started 3 days before immunization. Results: As compared with the EAE group, NIL animals developed just a mild clinical signs of EAE and significant decreased IFN‐γ and IL‐17 levels. NIL+DP treated animals restored its susceptibility to EAE clinical signs, whereas no‐significant differences on cytokine levels occurred. Significant differences in gene expression profile among groups were evident; in the NIL group the expression pattern of the TGF‐β pathway was down‐regulated as compared with the EAE group, whereas in the NIL+DP group the same genes were up‐regulated. Conclusions: Findings add novel data indicating that directly AVP plays a crucial role in regulating the immune responses and suggests that AVP receptor blockers may be used for the MS treatment and possibly autoimmune diseases and other inflammatory processes. Support or Funding Information Supported by UAA‐PIFF14‐1 and CONACYT‐221262 (AQS). México. VVB: CONACT Doctoral scholarship. NMS: CONACYT post doctoral Fellow. México. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
- Open Access
- 27 March 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (3) , e0194205
Transcriptional signature associated with early rheumatoid arthritis and healthy individuals at high risk to develop the disease
Little is known regarding the mechanisms underlying the loss of tolerance in the early and preclinical stages of autoimmune diseases. The aim of this work was to identify the transcriptional profile and signaling pathways associated to non-treated early rheumatoid arthritis (RA) and subjects at high risk. Several biomarker candidates for early RA are proposed. Whole blood total RNA was obtained from non-treated early RA patients with 0.92. These genes come from several functional categories associated to inflammation, Wnt signaling and type I interferon pathways. The presence of a specific transcriptome in whole blood of RA patients suggests the activation of a specific inflammatory transcriptional signature in early RA development. The set of overexpressed genes in early RA patients that are shared with ACCP+ subjects but not with ACCP- subjects, can represent a transcriptional signature involved with the transition of a preclinical to a clinical RA stage. Some of these particular up-regulated and down-regulated genes are related to inflammatory processes and could be considered as biomarker candidates for disease progression in subjects at risk to develop RA.
- 27 March 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (3) , e0194205
Open AccessTranscriptional signature associated with early rheumatoid arthritis and healthy individuals at high risk to develop the disease
Little is known regarding the mechanisms underlying the loss of tolerance in the early and preclinical stages of autoimmune diseases. The aim of this work was to identify the transcriptional profile and signaling pathways associated to non-treated early rheumatoid arthritis (RA) and subjects at high risk. Several biomarker candidates for early RA are proposed. Whole blood total RNA was obtained from non-treated early RA patients with 0.92. These genes come from several functional categories associated to inflammation, Wnt signaling and type I interferon pathways. The presence of a specific transcriptome in whole blood of RA patients suggests the activation of a specific inflammatory transcriptional signature in early RA development. The set of overexpressed genes in early RA patients that are shared with ACCP+ subjects but not with ACCP- subjects, can represent a transcriptional signature involved with the transition of a preclinical to a clinical RA stage. Some of these particular up-regulated and down-regulated genes are related to inflammatory processes and could be considered as biomarker candidates for disease progression in subjects at risk to develop RA.
- Open Access
- 20 March 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 285
Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production
Rheumatoid arthritis is an inflammatory debilitating disease that affects the joints in the early and productive phases of an individual’s life. Several cytokines have been linked to the disease pathogenesis and are known to contribute to the inflammatory state characteristic of RA. The participation of type I interferon (IFN) in the pathogenesis of the disease has been already described as well as the identity of the genes that are regulated by this molecule, which are collectively known as the type I IFN signature. These genes have several functions associated to apoptosis, transcriptional regulation, protein degradation, Th2 cell induction, B cell proliferation, etc. The present article evaluates the expression of the IFN signature in different stages of disease and their correlation with the levels of antibodies against citrullinated proteins (ACPA) and carbamylated proteins (Anti-CarP). Methods: Samples from individuals with early and established RA, high risk individuals (ACPA+ and ACPA-) and healthy controls were recruited at “Unidad de Artritis y Rheumatismo” (Rheumatism and Arthritis Unit) in Guadalajara Jalisco Mexico. Determinations of ACPA were made with Eurodiagnostica ACPA plus kit. Anti-CarP determinations were made according to previously described protocols. RNA was isolated and purity and integrity determined according to RIN > 6. Gene expression analysis was made by RT-qPCR using specific primers for mRNAs of the type I IFN signature. Relative gene expression was calculated according to (Livak and Schmitgen). Results: Significant differences in gene expression were identified when comparing the different groups for MXA and MXB (p<0.05), also when comparing established RA and ACPA- in both IFIT 1 and G15. Increased expression of ISG15 was identified (p<0.05) and a clear tendency toward increase was identified for HERC5. EPSTRI1, IFI6 and IFI35 were found to be elevated in the cRA and eRA respectively (p<0.05). Significant correlations were identified for the IFN signature genes with the levels of ACPA and Anti-CarP (p<0.05). Conclusion: Our data confirms previous observations in the role of IFN signature and the pathogenesis of RA. Also, we provide evidence of an association between IFN-signature genes (that regulate Th2 cells and B cell proliferation) with the levels Anti-CarP and ACPA autoantibodies.
- 20 March 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 285
Open AccessType I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production
Rheumatoid arthritis is an inflammatory debilitating disease that affects the joints in the early and productive phases of an individual’s life. Several cytokines have been linked to the disease pathogenesis and are known to contribute to the inflammatory state characteristic of RA. The participation of type I interferon (IFN) in the pathogenesis of the disease has been already described as well as the identity of the genes that are regulated by this molecule, which are collectively known as the type I IFN signature. These genes have several functions associated to apoptosis, transcriptional regulation, protein degradation, Th2 cell induction, B cell proliferation, etc. The present article evaluates the expression of the IFN signature in different stages of disease and their correlation with the levels of antibodies against citrullinated proteins (ACPA) and carbamylated proteins (Anti-CarP). Methods: Samples from individuals with early and established RA, high risk individuals (ACPA+ and ACPA-) and healthy controls were recruited at “Unidad de Artritis y Rheumatismo” (Rheumatism and Arthritis Unit) in Guadalajara Jalisco Mexico. Determinations of ACPA were made with Eurodiagnostica ACPA plus kit. Anti-CarP determinations were made according to previously described protocols. RNA was isolated and purity and integrity determined according to RIN > 6. Gene expression analysis was made by RT-qPCR using specific primers for mRNAs of the type I IFN signature. Relative gene expression was calculated according to (Livak and Schmitgen). Results: Significant differences in gene expression were identified when comparing the different groups for MXA and MXB (p<0.05), also when comparing established RA and ACPA- in both IFIT 1 and G15. Increased expression of ISG15 was identified (p<0.05) and a clear tendency toward increase was identified for HERC5. EPSTRI1, IFI6 and IFI35 were found to be elevated in the cRA and eRA respectively (p<0.05). Significant correlations were identified for the IFN signature genes with the levels of ACPA and Anti-CarP (p<0.05). Conclusion: Our data confirms previous observations in the role of IFN signature and the pathogenesis of RA. Also, we provide evidence of an association between IFN-signature genes (that regulate Th2 cells and B cell proliferation) with the levels Anti-CarP and ACPA autoantibodies.
- 1 January 2016
- Published by Elsevier in Clinical Immunology
- Vol. 162, 107-117
Transcriptional profiles discriminate patients with pulmonary tuberculosis from non-tuberculous individuals depending on the presence of non-insulin diabetes mellitus
- 1 January 2016
- Published by Elsevier in Clinical Immunology
- Vol. 162, 107-117
Transcriptional profiles discriminate patients with pulmonary tuberculosis from non-tuberculous individuals depending on the presence of non-insulin diabetes mellitus
- 1 April 2015
- Published by Elsevier in Archives of Medical Research
- Vol. 46 (3) , 221-227
Associated Risk Factors for Latent Tuberculosis Infection in Subjects with Diabetes
- 1 April 2015
- Published by Elsevier in Archives of Medical Research
- Vol. 46 (3) , 221-227
Associated Risk Factors for Latent Tuberculosis Infection in Subjects with Diabetes
- 1 August 2011
- Published by Elsevier in Human Immunology
- Vol. 72 (8) , 656-662
Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus
- 1 August 2011
- Published by Elsevier in Human Immunology
- Vol. 72 (8) , 656-662
Differential expression of antimicrobial peptides in active and latent tuberculosis and its relationship with diabetes mellitus